<code id='2EFEEFF7E7'></code><style id='2EFEEFF7E7'></style>
      • <acronym id='2EFEEFF7E7'></acronym>
      <center id='2EFEEFF7E7'><center id='2EFEEFF7E7'><tfoot id='2EFEEFF7E7'></tfoot></center><abbr id='2EFEEFF7E7'><dir id='2EFEEFF7E7'><tfoot id='2EFEEFF7E7'></tfoot><noframes id='2EFEEFF7E7'>
      • <optgroup id='2EFEEFF7E7'><strike id='2EFEEFF7E7'><sup id='2EFEEFF7E7'></sup></strike><code id='2EFEEFF7E7'></code></optgroup>
        5. <b id='2EFEEFF7E7'><label id='2EFEEFF7E7'><select id='2EFEEFF7E7'><dt id='2EFEEFF7E7'><span id='2EFEEFF7E7'></span></dt></select></label></b><u id='2EFEEFF7E7'></u>
          <i id='2EFEEFF7E7'><strike id='2EFEEFF7E7'><tt id='2EFEEFF7E7'><pre id='2EFEEFF7E7'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / knowledge      
           
     
           
      
          knowledge 
           
      
           
      
           
       2025-09-07 06:40:49 
   
      
           
      
           
                        
          knowledge  
          
                                   
                 
                                      author：comprehensive   
                                        
                                      
                                      Page View：44985
                                  
                                    
          
                                   
          Adam's take main illustration
          Molly Ferguson/STAT
          Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:
          A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.
          advertisement
          With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
                      
                              
          
                                 Previous article：

                                
                                          Wegovy improves function in certain heart failure patients
                                
                            
          Next article：  
                                      
                                          Bright Health sells Medicare Advantage business to Molina
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles